RhumbLine Advisers’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-50,632
| Closed | -$115K | – | 4373 |
|
|
2024
Q2 | $115K | Buy |
50,632
+49,665
| +5,136% | +$190K | ﹤0.01% | 3473 |
|
|
2024
Q1 | $4.18K | Hold |
967
| – | – | ﹤0.01% | 4003 |
|
|
2023
Q4 | $2.95K | Hold |
967
| – | – | ﹤0.01% | 4058 |
|
|
2023
Q3 | $1.39K | Hold |
967
| – | – | ﹤0.01% | 4152 |
|
|
2023
Q2 | $2.41K | Buy |
+967
| New | +$2.64K | ﹤0.01% | 4191 |
|
|
2022
Q2 | – | Sell |
-47,109
| Closed | -$358K | – | 3268 |
|
|
2022
Q1 | $358K | Sell |
47,109
-16
| -0% | -$152 | ﹤0.01% | 2579 |
|
|
2021
Q4 | $481K | Buy |
47,125
+65
| +0.1% | +$828 | ﹤0.01% | 2521 |
|
|
2021
Q3 | $632K | Buy |
47,060
+1,078
| +2% | +$17.6K | ﹤0.01% | 2437 |
|
|
2021
Q2 | $1.01M | Sell |
45,982
-3,496
| -7% | -$77.7K | ﹤0.01% | 2244 |
|
|
2021
Q1 | $1.19M | Sell |
49,478
-4,357
| -8% | -$101K | ﹤0.01% | 2128 |
|
|
2020
Q4 | $968K | Buy |
53,835
+5,718
| +12% | +$85.4K | ﹤0.01% | 2143 |
|
|
2020
Q3 | $556K | Sell |
48,117
-6,642
| -12% | -$110K | ﹤0.01% | 2241 |
|
|
2020
Q2 | $1.33M | Buy |
54,759
+7,043
| +15% | +$116K | ﹤0.01% | 1926 |
|
|
2020
Q1 | $526K | Buy |
47,716
+2,192
| +5% | +$40.9K | ﹤0.01% | 2142 |
|
|
2019
Q4 | $1.2M | Sell |
45,524
-315
| -0.7% | -$7.37K | ﹤0.01% | 1999 |
|
|
2019
Q3 | $1.04M | Buy |
45,839
+1,783
| +4% | +$56.2K | ﹤0.01% | 2014 |
|
|
2019
Q2 | $1.35M | Buy |
44,056
+14,241
| +48% | +$300K | ﹤0.01% | 1928 |
|
|
2019
Q1 | $495K | Buy |
29,815
+1,569
| +6% | +$29.8K | ﹤0.01% | 2333 |
|
|
2018
Q4 | $541K | Buy |
28,246
+9,772
| +53% | +$366K | ﹤0.01% | 2263 |
|
|
2018
Q3 | $966K | Sell |
18,474
-1,028
| -5% | -$56.1K | ﹤0.01% | 2018 |
|
|
2018
Q2 | $848K | Buy |
19,502
+7,772
| +66% | +$333K | ﹤0.01% | 2085 |
|
|
2018
Q1 | $435K | Buy |
+11,730
| New | +$313K | ﹤0.01% | 2269 |
|
RhumbLine Advisers's GTHX Position: Q3 2024 in Review
RhumbLine Advisers sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 50,632 shares — an estimated $115K sold.
RhumbLine Advisers first reported a position in GTHX in Q1 2018 and held it in 22 quarters. The position peaked at $1.35M in Q2 2019. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- RhumbLine Advisers reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- RhumbLine Advisers sold 50,632 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $115K.
- RhumbLine Advisers first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 22 quarters.
- RhumbLine Advisers's G1 Therapeutics, Inc. Common Stock position peaked at $1.35M in Q2 2019.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.